What is Ayogo?
Founded in 2008, Ayogo operates at the intersection of behavioral psychology and digital health technology. The company's core offering, the Glimpse Platform, is designed to address the persistent challenge of patient non-adherence by delivering personalized content and support tools tailored to individual psychosocial profiles. By integrating these insights into the patient journey, Ayogo enables healthcare providers and pharmaceutical companies to foster deeper engagement, ultimately improving clinical outcomes and long-term therapy persistence.
In an era where digital transformation is reshaping the healthcare landscape, Ayogo's market position is defined by its ability to bridge the gap between clinical requirements and patient behavior. The platform serves as a vital layer in the modern digital health stack, providing the necessary tools to convert passive patients into active participants in their own care management.
How much funding has Ayogo raised?
Ayogo has raised a total of $10M across 2 funding rounds:
Series A
$2.5M
Series B
$7.5M
Series A (2015): $2.5M with participation from Excel Venture Management, 7Wire Ventures, and Merck Global Health Innovations
Series B (2020): $7.5M led by 7Wire Ventures, Excel Venture Management, MEDTEQ, Merck Global Health Innovation Fund, and Baxter International Inc
Key Investors in Ayogo
Excel Venture Management
A venture capital firm specializing in early-stage and growth-stage investments within the life sciences and healthcare technology sectors.
7Wire Ventures
An investment firm focused on the connected health market, supporting companies that empower consumers to be better stewards of their health.
Merck Global Health Innovation Fund
The strategic investment arm of Merck & Co., Inc., dedicated to funding innovative healthcare solutions that improve patient outcomes and operational efficiency.
What's next for Ayogo?
With the recent infusion of capital, Ayogo is well-positioned to scale its enterprise operations and expand the reach of its Glimpse Platform. The strategic focus will likely center on deepening integrations with global pharmaceutical partners and enhancing the platform's predictive analytics capabilities. As the digital therapeutics market continues to mature, Ayogo's ability to demonstrate measurable improvements in patient adherence will be a key driver of its future valuation and market influence.
The company is expected to leverage its current financial standing to explore new therapeutic areas and potentially expand its footprint in international markets. By maintaining its focus on evidence-based behavioral interventions, Ayogo remains a key player to watch in the evolving landscape of patient engagement and digital health innovation.
